Market Closed -
Nasdaq
04:00:00 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
13.65
USD
|
-1.09%
|
|
-7.27%
|
+27.57%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
102
|
156.8
|
26.8
|
457.2
|
827.2
|
-
|
-
|
Enterprise Value (EV)
1 |
102
|
156.8
|
26.8
|
457.2
|
827.2
|
827.2
|
827.2
|
P/E ratio
|
-1.84
x
|
-6.06
x
|
-0.72
x
|
-1.99
x
|
-3.88
x
|
-5.08
x
|
-3.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
32.6
x
|
82.4
x
|
980
x
|
56.1
x
|
EV / Revenue
|
-
|
-
|
-
|
32.6
x
|
82.4
x
|
980
x
|
56.1
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-3.91
x
|
-5.73
x
|
-
|
EV / FCF
|
-8.02
x
|
-
|
-
|
-54.4
x
|
-4.74
x
|
-6.57
x
|
-7.52
x
|
FCF Yield
|
-12.5%
|
-
|
-
|
-1.84%
|
-21.1%
|
-15.2%
|
-13.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,542
|
12,100
|
12,129
|
42,730
|
59,943
|
-
|
-
|
Reference price
2 |
9.680
|
12.96
|
2.210
|
10.70
|
13.80
|
13.80
|
13.80
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
14.02
|
10.04
|
0.844
|
14.75
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-211.6
|
-144.3
|
-
|
EBIT
1 |
-
|
-12.26
|
-25.2
|
-36.9
|
-28.73
|
-207.5
|
-157.2
|
-196.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-204.94%
|
-2,065.72%
|
-18,631.13%
|
-1,332.38%
|
Earnings before Tax (EBT)
1 |
-
|
-17.84
|
-
|
-36.9
|
-106.8
|
-202.7
|
-151.2
|
-193.7
|
Net income
1 |
-10.44
|
-17.84
|
-24.71
|
-37.52
|
-106.8
|
-192.8
|
-169.8
|
-227.1
|
Net margin
|
-
|
-
|
-
|
-
|
-761.92%
|
-1,919.49%
|
-20,122.31%
|
-1,540.33%
|
EPS
2 |
-0.3200
|
-5.260
|
-2.140
|
-3.090
|
-5.380
|
-3.557
|
-2.715
|
-3.525
|
Free Cash Flow
1 |
-
|
-12.72
|
-
|
-
|
-8.399
|
-174.5
|
-126
|
-110
|
FCF margin
|
-
|
-
|
-
|
-
|
-59.92%
|
-1,737.26%
|
-14,929.09%
|
-745.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/9/20
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
2.364
|
-
|
-
|
3.826
|
1.029
|
2.8
|
2.8
|
3.35
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.844
|
-11.65
|
-8.926
|
-8.534
|
-7.787
|
-4.471
|
-
|
-
|
-13.85
|
-132.3
|
-24.17
|
-24.67
|
-26.6
|
-31.5
|
-34
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-189.13%
|
-
|
-
|
-362.02%
|
-12,857.05%
|
-863.1%
|
-880.95%
|
-794.03%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-8.533
|
-7.786
|
-4.27
|
-
|
-
|
-92.63
|
-129.5
|
-22.13
|
-22.73
|
-28.3
|
-30.3
|
-31.45
|
Net income
1 |
-7.852
|
-11.65
|
-8.924
|
-9.155
|
-7.786
|
-4.27
|
-
|
-4.345
|
-92.63
|
-129.5
|
-19
|
-20
|
-24.28
|
-30.3
|
-31.45
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-180.63%
|
-
|
-
|
-2,421.17%
|
-12,584.26%
|
-678.57%
|
-714.29%
|
-724.63%
|
-
|
-
|
EPS
2 |
-0.6500
|
-0.9600
|
-0.7400
|
-0.7500
|
-0.6400
|
-0.3500
|
-0.4600
|
-0.3600
|
-4.220
|
-2.510
|
-0.3499
|
-0.3657
|
-0.4309
|
-0.6167
|
-0.6233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/12/22
|
8/5/22
|
11/14/22
|
3/16/23
|
5/5/23
|
8/9/23
|
11/9/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-12.7
|
-
|
-
|
-8.4
|
-175
|
-126
|
-110
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-110%
|
-42.9%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-87%
|
-36%
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
221.5
|
471.3
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.59
|
0.08
|
0.25
|
0.83
|
4.5
|
4.3
|
2.75
|
Capex / Sales
|
-
|
-
|
-
|
-
|
5.93%
|
44.8%
|
509.48%
|
18.65%
|
Announcement Date
|
9/9/20
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
13.8
USD Average target price
32.5
USD Spread / Average Target +135.51% Consensus |
1st Jan change
|
Capi.
|
---|
| +27.57% | 827M | | +8.63% | 115B | | +13.17% | 107B | | -12.76% | 22.31B | | -3.99% | 21.6B | | -7.19% | 18.23B | | -39.93% | 17.62B | | +6.67% | 14.26B | | +33.90% | 12.37B | | -28.60% | 8.28B |
Bio Therapeutic Drugs
|